Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Hospital costs associated with adverse events in people with diabetes in the UK.

Keng MJ. et al, (2022), Diabetes Obes Metab

BEHRTDAY: Dynamic Mortality Risk Prediction using Time-Variant COVID-19 Patient Specific Trajectories

Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1

Using Shapes of COVID-19 Positive Patient-Specific Trajectories for Mortality Prediction

Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1

CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA

Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: The Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ)

Roukas C. et al, (2022), Frontline Gastroenterology

EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS

Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12

P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments

Zhou J. et al, (2022), Value in Health, 25, S12 - S12

P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data

Wu R. et al, (2022), Value in Health, 25, S16 - S16

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group Writing Committee: None. et al, (2021), Eur Heart J

Decrements in health-related quality of life associated with adverse events in people with diabetes.

Keng MJ. et al, (2021), Diabetes Obes Metab

Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK

Wu R. et al, (2021), BMJ Open, 11, e052884 - e052884

A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149

Benefits from optimised antihypertensive and statin treatment in high risk people

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 2728 - 2728

Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention

Lui NMJ. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3159 - 3159

Daily life and challenges faced by households with permanent childhood developmental disability in rural Tanzania – a qualitative study

Castellani J. et al, (2021), Journal of Developmental and Physical Disabilities

Performance of the UKPDS Outcomes Model 2 in a contemporary UK type 2 diabetes trial cohort

Keng MJ. et al, (2021), Value in Health

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

Halliday A. et al, (2021), Lancet

Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme

Perera R. et al, (2021), Programme Grants for Applied Research, 9, 1 - 218

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).

Leal J. et al, (2021), Diabet Med

Supported Online Self-Management Versus Care as Usual for Symptoms of Fatigue, Pain and Urgency/incontinence in Adults With Inflammatory Bowel Disease (IBD-BOOST): Study Protocol for a Randomized Controlled Trial.

Norton C. et al, (2021)

Load More

1
2
3
4
5
6

Include forthcoming?